The layoff, which is primarily in the area of research and development, is expected to be substantially complete by the end of 2019. Market Events Features In after-hours, the stock was up 119.90% to $18.45.Millendo Therapeutics Inc. (MLND) has offered to sell 4.16 million shares of its common stock to the public at a price of $6.00 per share.The aggregate gross proceeds from the offering are expected to be $25.0 million. Avadel Pharmaceuticals. Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of … Nasdaq Data We are a global pharmaceutical company, proud to be unique in our space as experts in the development and commercialization of safe, novel products that address unmet medical needs through improved dosing and by ensuring the safety and efficacy of … US Markets Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.Tyson Foods and Royal Caribbean are among companies that have added chief medical officers to their executive teams amid the coronavirus pandemic.Tyson Foods and Royal Caribbean are among companies that have added chief medical officers to their executive teams amid the coronavirus pandemic.ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Roughly the same number of positions are getting culled at the California offices of AbbVie's Stemcentrx. The offering is expected to close on December 6, 2019, subject to customary closing conditions.In addition, Relmada has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of Relmada's common stock.On October 15, 2019, the Company reported promising results from its phase II clinical study evaluating two doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with treatment-resistant depression.
While the industry is also creating new roles, more layoffs are on the way as large employers like Above, we've created a map to help visualize where these job cuts are happening.
Stock futures point to positive finish for volatile week on Wall Street Aslan Pharmaceuticals announces secondary offering of stockAslan Pharmaceuticals stock price target cut to $3 from $4 at SVB Leerink #TradeTalks: What is the Next Catalyst Outside of the Known that Could Set the Narrative for the Market?#TradeTalks: The Charles Schwab Active Trader Pulse Survey#TradeTalks: The Recent Selloff in Stocks and What Technical Indicators to Watch7 Explosive Cryptocurrencies to Buy for the Bitcoin Halvening3 Safe Dividend Stocks Yielding 5%; Analysts Say ‘Buy’The Market is Sending Mixed Messages: What Should Investors Do?var dom1 = document.querySelector('#form1783 #field1');var field1 = new LiveValidation(dom1, {validMessage: "", onlyOnBlur: false, wait: 300});field1.add(Validate.Presence, {failureMessage:"This field is required"});field1.add(Validate.Format, {pattern: /^([^@\s]+)@((?:[-a-z0-9]+\. The free newsletter covering the top industry headlinesTopics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more.The free newsletter covering the top industry headlinesTopics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. Allena Pharmaceuticals hired Edward Wholihan as chief financial officer; AMAG Pharmaceuticals hired Tony Casciano as senior vice president of sales and marketing; RTTNews.com 3 Safe Dividend Stocks Yielding 5%; Analysts Say ‘Buy’ AUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims Workforce ACAD closed Wednesday's trading at $44.28, down 1.47%. In after-hours, the stock was down 18.81% to $6.30.Relmada Therapeutics Inc. (RLMD) has offered to sell 3.33 million shares of its common stock to the public at a price of $30.00 per share in an underwritten offering.
This condition can cause kidney stones, damaging the kidney - ultimately leading to kidney failure.Last month, the Company reported positive topline results from a pivotal phase III trial of Reloxaliase for the treatment of patients with enteric hyperoxaluria, dubbed URIROX-1.
Weekly Preview: Stocks To Watch (LULU, PTON, WORK, ZS) Also in the pipeline is MLE-301 in pre-clinical development for the treatment of vasomotor symptoms associated with menopause.Livoletide is under a pivotal phase IIb/III clinical study in patients with Prader-Willi syndrome, dubbed ZEPHYR, with topline results expected in 1H20.
Nevanimibe is under a phase IIb study in patients with congenital adrenal hyperplasia, and includes two distinct cohorts of patients.